• Je něco špatně v tomto záznamu ?

Discovery of Dual Aβ/Tau Inhibitors and Evaluation of Their Therapeutic Effect on a Drosophila Model of Alzheimer's Disease

A. Gandini, AE. Gonçalves, S. Strocchi, C. Albertini, J. Janočková, A. Tramarin, D. Grifoni, E. Poeta, O. Soukup, D. Muñoz-Torrero, B. Monti, R. Sabaté, M. Bartolini, G. Legname, ML. Bolognesi

. 2022 ; 13 (23) : 3314-3329. [pub] 20221129

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032229

Alzheimer's disease (AD), the most common type of dementia, currently represents an extremely challenging and unmet medical need worldwide. Amyloid-β (Aβ) and Tau proteins are prototypical AD hallmarks, as well as validated drug targets. Accumulating evidence now suggests that they synergistically contribute to disease pathogenesis. This could not only help explain negative results from anti-Aβ clinical trials but also indicate that therapies solely directed at one of them may have to be reconsidered. Based on this, herein, we describe the development of a focused library of 2,4-thiazolidinedione (TZD)-based bivalent derivatives as dual Aβ and Tau aggregation inhibitors. The aggregating activity of the 24 synthesized derivatives was tested in intact Escherichia coli cells overexpressing Aβ42 and Tau proteins. We then evaluated their neuronal toxicity and ability to cross the blood-brain barrier (BBB), together with the in vitro interaction with the two isolated proteins. Finally, the most promising (most active, nontoxic, and BBB-permeable) compounds 22 and 23 were tested in vivo, in a Drosophila melanogaster model of AD. The carbazole derivative 22 (20 μM) showed extremely encouraging results, being able to improve both the lifespan and the climbing abilities of Aβ42 expressing flies and generating a better outcome than doxycycline (50 μM). Moreover, 22 proved to be able to decrease Aβ42 aggregates in the brains of the flies. We conclude that bivalent small molecules based on 22 deserve further attention as hits for dual Aβ/Tau aggregation inhibition in AD.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032229
003      
CZ-PrNML
005      
20230131151648.0
007      
ta
008      
230120s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acschemneuro.2c00357 $2 doi
035    __
$a (PubMed)36445009
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Gandini, Annachiara $u Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Via Belmeloro 6, I-40126Bologna, Italy $u Department of Neuroscience, Laboratory of Prion Biology, Scuola Internazionale Superiore di Studi Avanzati (SISSA), Via Bonomea 265, I-34136Trieste, Italy $1 https://orcid.org/0000000228889636
245    10
$a Discovery of Dual Aβ/Tau Inhibitors and Evaluation of Their Therapeutic Effect on a Drosophila Model of Alzheimer's Disease / $c A. Gandini, AE. Gonçalves, S. Strocchi, C. Albertini, J. Janočková, A. Tramarin, D. Grifoni, E. Poeta, O. Soukup, D. Muñoz-Torrero, B. Monti, R. Sabaté, M. Bartolini, G. Legname, ML. Bolognesi
520    9_
$a Alzheimer's disease (AD), the most common type of dementia, currently represents an extremely challenging and unmet medical need worldwide. Amyloid-β (Aβ) and Tau proteins are prototypical AD hallmarks, as well as validated drug targets. Accumulating evidence now suggests that they synergistically contribute to disease pathogenesis. This could not only help explain negative results from anti-Aβ clinical trials but also indicate that therapies solely directed at one of them may have to be reconsidered. Based on this, herein, we describe the development of a focused library of 2,4-thiazolidinedione (TZD)-based bivalent derivatives as dual Aβ and Tau aggregation inhibitors. The aggregating activity of the 24 synthesized derivatives was tested in intact Escherichia coli cells overexpressing Aβ42 and Tau proteins. We then evaluated their neuronal toxicity and ability to cross the blood-brain barrier (BBB), together with the in vitro interaction with the two isolated proteins. Finally, the most promising (most active, nontoxic, and BBB-permeable) compounds 22 and 23 were tested in vivo, in a Drosophila melanogaster model of AD. The carbazole derivative 22 (20 μM) showed extremely encouraging results, being able to improve both the lifespan and the climbing abilities of Aβ42 expressing flies and generating a better outcome than doxycycline (50 μM). Moreover, 22 proved to be able to decrease Aβ42 aggregates in the brains of the flies. We conclude that bivalent small molecules based on 22 deserve further attention as hits for dual Aβ/Tau aggregation inhibition in AD.
650    _2
$a zvířata $7 D000818
650    12
$a Alzheimerova nemoc $x farmakoterapie $7 D000544
650    _2
$a Drosophila $7 D004330
650    _2
$a proteiny tau $7 D016875
650    _2
$a Drosophila melanogaster $7 D004331
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gonçalves, Ana Elisa $u Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Via Belmeloro 6, I-40126Bologna, Italy $u Pharmaceutical Sciences Postgraduate Program, Center of Health Sciences, Universidade do Vale do Itajaí, Rua Uruguai 458, 88302-202Itajaí, Santa Catarina, Brazil
700    1_
$a Strocchi, Silvia $u Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Via Belmeloro 6, I-40126Bologna, Italy
700    1_
$a Albertini, Claudia $u Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Via Belmeloro 6, I-40126Bologna, Italy
700    1_
$a Janočková, Jana $u Biomedical Research Center, University Hospital Hradec Kralove, 500 00Hradec Kralove, Czech Republic
700    1_
$a Tramarin, Anna $u Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Via Belmeloro 6, I-40126Bologna, Italy
700    1_
$a Grifoni, Daniela $u Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Via Belmeloro 6, I-40126Bologna, Italy $u Department of Life, Health and Environmental Sciences, University of L'Aquila, Via Vetoio, Coppito II, 67100L'Aquila, Italy
700    1_
$a Poeta, Eleonora $u Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Via Belmeloro 6, I-40126Bologna, Italy
700    1_
$a Soukup, Ondrej $u Biomedical Research Center, University Hospital Hradec Kralove, 500 00Hradec Kralove, Czech Republic $1 https://orcid.org/0000000163768701
700    1_
$a Muñoz-Torrero, Diego $u Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona (UB), Av. Joan XXIII 27-31, E-08028Barcelona, Spain $1 https://orcid.org/0000000281408555
700    1_
$a Monti, Barbara $u Pharmaceutical Sciences Postgraduate Program, Center of Health Sciences, Universidade do Vale do Itajaí, Rua Uruguai 458, 88302-202Itajaí, Santa Catarina, Brazil $1 https://orcid.org/000000030330482X
700    1_
$a Sabaté, Raimon $u Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Av Joan XXIII 27-31, E-08028Barcelona, Spain $1 https://orcid.org/0000000338942362
700    1_
$a Bartolini, Manuela $u Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Via Belmeloro 6, I-40126Bologna, Italy $1 https://orcid.org/0000000228903856
700    1_
$a Legname, Giuseppe $u Department of Neuroscience, Laboratory of Prion Biology, Scuola Internazionale Superiore di Studi Avanzati (SISSA), Via Bonomea 265, I-34136Trieste, Italy $1 https://orcid.org/0000000307164393
700    1_
$a Bolognesi, Maria Laura $u Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, Via Belmeloro 6, I-40126Bologna, Italy $1 https://orcid.org/0000000212895361
773    0_
$w MED00193636 $t ACS chemical neuroscience $x 1948-7193 $g Roč. 13, č. 23 (2022), s. 3314-3329
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36445009 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151644 $b ABA008
999    __
$a ok $b bmc $g 1891153 $s 1183564
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 13 $c 23 $d 3314-3329 $e 20221129 $i 1948-7193 $m ACS chemical neuroscience $n ACS Chem Neurosci $x MED00193636
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Možnosti archivace